148 related articles for article (PubMed ID: 34303841)
1. Nano-multilamellar lipid vesicles loaded with a recombinant form of the chikungunya virus E2 protein improve the induction of virus-neutralizing antibodies.
Venceslau-Carvalho AA; Teixeira de Pinho Favaro M; Ramos Pereira L; Rodrigues-Jesus MJ; Santos Pereira S; Andreata-Santos R; Dos Santos Alves RP; Castro-Amarante MF; Bitencourt Rodrigues K; Ramos da Silva J; Rahal Guaragna Machado R; Dos Passos Cunha M; Marinho de Andrade Zanotto P; Luzetti Fotoran W; Wunderlich G; Durigon EL; de Souza Ferreira LC
Nanomedicine; 2021 Oct; 37():102445. PubMed ID: 34303841
[TBL] [Abstract][Full Text] [Related]
2. Anti-Chikungunya Virus Monoclonal Antibody That Inhibits Viral Fusion and Release.
Tumkosit U; Siripanyaphinyo U; Takeda N; Tsuji M; Maeda Y; Ruchusatsawat K; Shioda T; Mizushima H; Chetanachan P; Wongjaroen P; Matsuura Y; Tatsumi M; Tanaka A
J Virol; 2020 Sep; 94(19):. PubMed ID: 32699087
[TBL] [Abstract][Full Text] [Related]
3. An mRNA vaccine encoding Chikungunya virus E2-E1 protein elicits robust neutralizing antibody responses and CTL immune responses.
Ge N; Sun J; Liu Z; Shu J; Yan H; Kou Z; Wei Y; Jin X
Virol Sin; 2022 Apr; 37(2):266-276. PubMed ID: 35527225
[TBL] [Abstract][Full Text] [Related]
4. A small antigenic determinant of the Chikungunya virus E2 protein is sufficient to induce neutralizing antibodies which are partially protective in mice.
Weber C; Büchner SM; Schnierle BS
PLoS Negl Trop Dis; 2015 Apr; 9(4):e0003684. PubMed ID: 25905779
[TBL] [Abstract][Full Text] [Related]
5. Chikungunya-specific IgG and neutralizing antibody responses in natural infection of Chikungunya virus in children from India.
Verma A; Nayak K; Chandele A; Singla M; Ratageri VH; Lodha R; Kabra SK; Murali-Krishna K; Ray P
Arch Virol; 2021 Jul; 166(7):1913-1920. PubMed ID: 33907861
[TBL] [Abstract][Full Text] [Related]
6. A potent neutralizing IgM mAb targeting the N218 epitope on E2 protein protects against Chikungunya virus pathogenesis.
Lam S; Nyo M; Phuektes P; Yew CW; Tan YJ; Chu JJ
MAbs; 2015; 7(6):1178-94. PubMed ID: 26305993
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of neutralizing antibodies produced by papaya mosaic virus nanoparticles fused to the E2EP3 peptide epitope of Chikungunya envelope.
Nor Rashid N; Teoh TC; Al-Harbi SJ; Yusof R; Rothan HA
Trop Biomed; 2021 Mar; 38(1):36-41. PubMed ID: 33797522
[TBL] [Abstract][Full Text] [Related]
8. Co-Immunization With CHIKV VLP and DNA Vaccines Induces a Promising Humoral Response in Mice.
Zhao Z; Deng Y; Niu P; Song J; Wang W; Du Y; Huang B; Wang W; Zhang L; Zhao P; Tan W
Front Immunol; 2021; 12():655743. PubMed ID: 33868299
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of recombinant E2 protein-based and whole-virus inactivated candidate vaccines against chikungunya virus.
Kumar M; Sudeep AB; Arankalle VA
Vaccine; 2012 Sep; 30(43):6142-9. PubMed ID: 22884660
[TBL] [Abstract][Full Text] [Related]
10. A novel poxvirus-based vaccine, MVA-CHIKV, is highly immunogenic and protects mice against chikungunya infection.
García-Arriaza J; Cepeda V; Hallengärd D; Sorzano CÓ; Kümmerer BM; Liljeström P; Esteban M
J Virol; 2014 Mar; 88(6):3527-47. PubMed ID: 24403588
[TBL] [Abstract][Full Text] [Related]
11. Exposure of epitope residues on the outer face of the chikungunya virus envelope trimer determines antibody neutralizing efficacy.
Fong RH; Banik SS; Mattia K; Barnes T; Tucker D; Liss N; Lu K; Selvarajah S; Srinivasan S; Mabila M; Miller A; Muench MO; Michault A; Rucker JB; Paes C; Simmons G; Kahle KM; Doranz BJ
J Virol; 2014 Dec; 88(24):14364-79. PubMed ID: 25275138
[TBL] [Abstract][Full Text] [Related]
12. Unique epitopes recognized by antibodies induced in Chikungunya virus-infected non-human primates: implications for the study of immunopathology and vaccine development.
Kam YW; Lee WW; Simarmata D; Le Grand R; Tolou H; Merits A; Roques P; Ng LF
PLoS One; 2014; 9(4):e95647. PubMed ID: 24755730
[TBL] [Abstract][Full Text] [Related]
13. Antigenic Variation of East/Central/South African and Asian Chikungunya Virus Genotypes in Neutralization by Immune Sera.
Chua CL; Sam IC; Merits A; Chan YF
PLoS Negl Trop Dis; 2016 Aug; 10(8):e0004960. PubMed ID: 27571254
[TBL] [Abstract][Full Text] [Related]
14. Development of Vaccines for Chikungunya Fever.
Erasmus JH; Rossi SL; Weaver SC
J Infect Dis; 2016 Dec; 214(suppl 5):S488-S496. PubMed ID: 27920179
[TBL] [Abstract][Full Text] [Related]
15. Development of a Specific CHIKV-E2 Monoclonal Antibody for Chikungunya Diagnosis.
Kim J; Yang J; Kim YB; Lee HJ; Kim S; Poo H
Virol Sin; 2019 Oct; 34(5):563-571. PubMed ID: 31214999
[TBL] [Abstract][Full Text] [Related]
16. Early neutralizing IgG response to Chikungunya virus in infected patients targets a dominant linear epitope on the E2 glycoprotein.
Kam YW; Lum FM; Teo TH; Lee WW; Simarmata D; Harjanto S; Chua CL; Chan YF; Wee JK; Chow A; Lin RT; Leo YS; Le Grand R; Sam IC; Tong JC; Roques P; Wiesmüller KH; Rénia L; Rötzschke O; Ng LF
EMBO Mol Med; 2012 Apr; 4(4):330-43. PubMed ID: 22389221
[TBL] [Abstract][Full Text] [Related]
17. A lipid-encapsulated mRNA encoding a potently neutralizing human monoclonal antibody protects against chikungunya infection.
Kose N; Fox JM; Sapparapu G; Bombardi R; Tennekoon RN; de Silva AD; Elbashir SM; Theisen MA; Humphris-Narayanan E; Ciaramella G; Himansu S; Diamond MS; Crowe JE
Sci Immunol; 2019 May; 4(35):. PubMed ID: 31101672
[TBL] [Abstract][Full Text] [Related]
18. A recombinant virus vaccine that protects against both Chikungunya and Zika virus infections.
Chattopadhyay A; Aguilar PV; Bopp NE; Yarovinsky TO; Weaver SC; Rose JK
Vaccine; 2018 Jun; 36(27):3894-3900. PubMed ID: 29807712
[TBL] [Abstract][Full Text] [Related]
19. Recombinant modified vaccinia virus Ankara expressing glycoprotein E2 of Chikungunya virus protects AG129 mice against lethal challenge.
van den Doel P; Volz A; Roose JM; Sewbalaksing VD; Pijlman GP; van Middelkoop I; Duiverman V; van de Wetering E; Sutter G; Osterhaus AD; Martina BE
PLoS Negl Trop Dis; 2014 Sep; 8(9):e3101. PubMed ID: 25188230
[TBL] [Abstract][Full Text] [Related]
20. Liposomal Delivery of the RNA Genome of a Live-Attenuated Chikungunya Virus Vaccine Candidate Provides Local, but Not Systemic Protection After One Dose.
Abeyratne E; Tharmarajah K; Freitas JR; Mostafavi H; Mahalingam S; Zaid A; Zaman M; Taylor A
Front Immunol; 2020; 11():304. PubMed ID: 32194557
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
